Abstract
Background
It has long been noted that the chain from identification of need (research gap) to impact in the real world is both long and tortuous. This study aimed to contribute evidence about research ethics and governance arrangements and processes in the UK with a focus on: what works well; problems; impacts on delivery; and potential improvements.
Methods
Online questionnaire widely distributed 20th May 2021, with request to forward to other interested parties. The survey closed on 18th June 2021. Questionnaire included closed and open questions related to demographics, role, study objectives.
Results
Responses were received from 252 respondents, 68% based in universities 25% in the NHS. Research methods used by respondents included interviews/focus groups (64%); surveys/questionnaires (63%); and experimental/quasi experimental (57%). Respondents reported that participants in the research they conducted most commonly included: patients (91%); NHS staff (64%) and public (50%). Aspects of research ethics and governance reported to work well were: online centralised systems; confidence in rigorous, respected systems; and helpful staff. Problems with workload, frustration and delays were reported, related to overly bureaucratic, unclear, repetitive, inflexible and inconsistent processes. Disproportionality of requirements for low-risk studies was raised across all areas, with systems reported to be risk averse, defensive and taking little account of the risks associated with delaying or deterring research. Some requirements were reported to have unintended effects on inclusion and diversity, particularly impacting Patient and Public Involvement (PPI) and engagement processes. Existing processes and requirements were reported to cause stress and demoralisation, particularly as many researchers are employed on fixed term contracts. High negative impacts on research delivery were reported, in terms of timescales for completing studies, discouraging research particularly for clinicians and students, quality of outputs and costs. Suggested improvements related to system level changes / overall approach and specific refinements to existing processes.
Conclusions
Consultation with those involved in Health Services Research in the UK revealed a picture of overwhelming and increasing bureaucracy, delays, costs and demoralisation related to gaining the approvals necessary to conduct research in the NHS. Suggestions for improvement across all three areas focused on reducing duplication and unnecessary paperwork/form filling and reaching a better balance between risks of harm through research and harms which occur because research to inform practice is delayed or deterred.
Keywords: Health services research, Ethics, Governance, Online survey
Introduction
Despite wide acceptance of the desirability of basing practice and policy in healthcare on rigorous evidence of safety and cost-effectiveness, it has long been noted that the chain from identification of need (research gap) to impact in the real world is both long and tortuous [1, 2]. Initiatives have tried to address hold ups at each stage so that research funding is well spent to deliver research findings that are relevant, timely and implemented to achieve real improvements in care delivered and health outcomes for patients or across populations [3]. Although rapid evaluation and evidence dissemination centres have been commissioned [4, 5] to try to speed up the production of evidence, researchers remain vulnerable to criticism for producing high quality evidence too slowly for decision makers to use that evidence in policy or practice guidance, planning and decision-making [6–8].
Health Services Research (HSR) is a multidisciplinary field that investigates healthcare service organisation, access, quality and costs in order to improve health and well-being of patients and populations [9]. Health care innovations are of particular interest. Many healthcare policies and practices continue to be implemented widely without evidence of effectiveness [10, 11].
In this paper we focus on the links in the chain of research production and implementation which relate to the permissions required to carry out research in NHS settings in the UK. Health services researchers need to gain permissions in order to set up and undertake research with patients, the public or members of staff based in NHS settings – these permissions cover ethical approval; capability and capacity of sites to participate; data protection compliance; and information governance.
There have been many attempts to streamline processes for ethics and governance in the UK, with the formation of the Health Research Authority (HRA) in 2011. Since 2016 in England, and 2018 in England and Wales, there has been a unified system for applying for approvals for all project-based research in the NHS. Figure 1, below, summarises the processes to be followed before research can start.
Aims
The aim of this study was to identify and assess the views and experiences of those involved in HSR, within three key areas; research ethics, research governance, and information governance.
On behalf of HSRUK, the authors collaborated with the Health Research Authority (HRA), National Institute for Health Research (NIHR) and other partners to consult with those undertaking or affected by HSR in the UK to understand experiences and views related to:
What works well
Problems
Impact on delivery of research
Looking forward – improvements
Method
Online survey
An online consultation survey was widely distributed from 20th May 2021 and closed on 18th June 2021. Invitations to participants included a request to forward the survey link to others, using a snowball sampling approach. The sample consisted of HSR UK member organisations (n = 41), those on the HSR UK mailing list (n = 4212), and followers of the HSR UK Twitter account (n = 4609), who were actively encouraged to retweet it.
Questionnaire
The questionnaire was designed by HSRUK Board members and partners (authors HS, KW, RB, AK) to include closed questions related to demographics and role; and open questions related to our study objectives: what works well; problems (if any); impact on delivery (if any); differences during the COVID-19 pandemic; suggestions for improvement in the three domains of research ethics, research governance and information governance.
Closed (categorical) questionnaire responses such as place of work and role were analysed descriptively and are presented without further manipulation. Open (narrative) questionnaire responses were coded thematically within each question and domain. Responses were split by theme so that if one respondent reported several aspects within one response (e.g. delays, stress, costs) this one response would be assigned to three codes. Results are presented by coded comments rather than by respondent so that there may be more coded responses that total respondents in any one question/domain. Quotations are provided to illustrate comments made – and where these varied widely, more quotations are provided to demonstrate the range of responses.
Results
Characteristics of respondents
Completed responses were received from 252 people. Over two thirds were based in universities (68%, n = 172) with a further quarter based in the NHS (25%, n = 61). Other respondents reported that they were based in charities (n = 4), the Academic Health Science Network (n = 2), non-NHS healthcare providers (n = 2), local authority (n = 1) and pharmaceutical company (n = 1).
Two thirds described themselves as academic/researcher (66%, n = 164); a further 10% as NHS clinician (n = 24); 7% as research administrator (n = 17); 4% as student (n = 9) and others as clinical lecturer (n = 2), evaluator (n = 2), Patient/Public involvement/engagement person (n = 1), commissioner (n = 1) or Medical Officer (n = 1).
Almost half of respondents reported that they had been named as lead (principal/lead) investigator for externally funded research (41%, n = 148).
Research methods respondents reported they used included (respondents could tick more than one box): interviews/focus groups (64%, n = 160); surveys/questionnaires (63%, n = 159); experimental/quasi experimental (57%, n = 146); analysis of existing routine data (43%, n = 107); observation/ethnography (39%, n = 97); with small numbers reporting involvement in evidence synthesis (n = 2); participatory research/co-production (n = 2); health economics (n = 1); and biomedical research (n = 1).
Most respondents carried out research with patients as participants (91%, n = 229); with 64% reporting that they carried out research with NHS staff (n = 162) and half reporting their research involved members of the public (n = 126). Small numbers reported carrying out research with other (non-NHS) professionals (n = 13); social care users (n = 5); policy makers (n = 4), commissioners (n = 2); carers (n = 1); and other researchers (n = 1).
What worked well
The availability of national co-ordinated systems was valued across all three areas of ethics and governance (n = 118). Respondents felt that processes were rigorous and well respected (n = 58), giving confidence to researchers that they were following acceptable standards, particularly when research included vulnerable participants (n = 9) (Table 1). Some respondents felt that processes and requirements were clear (n = 50). HRA and other staff were reported to be helpful in supporting development and submission of applications for ethical or governance approval. A minority of respondents reported that systems were well designed and transparent, and applications could be shared between investigators (n = 6).
Table 1.
Theme | Total across areas n | Research ethics n | Research governance n | Information governance n | Key quotations |
---|---|---|---|---|---|
National co-ordinated system in place | 118 | 56 | 46 | 16 | One system to access information on all approval forms and submit applications … is good (RE) |
Robust | 58 | 24 | 22 | 12 | The external assurance granted that research has been thoroughly assessed and deemed legal and ethical should not be underestimated (IG) |
Helpful, friendly, supportive staff | 59 | 14 | 30 | 15 | Individuals handing the applications tend to be helpful and supportive (RG) |
Clarity | 50 | 20 | 19 | 11 | The quick HRA check about whether ethical approvals are required (RE) |
Speed/ timeliness | 28 | 22 | 6 | - | There is a timely response once the application is submitted (RE) |
Online/ virtual process | 22 | 22 | - | - | Thorough online systems accessible from home, by different project members (RE) |
Availability of guidance | 15 | 7 | - | 8 | The guidance and support has been clarified to a much better standard recently (IG) |
Proportionate review | 15 | 15 | - | - | Having a fast-track system for low-risk research is helpful, except that the bar is far too high (RE) |
Feedback strengthening study | 14 | 14 | - | - | Feedback from ethics committees can be very helpful in shaping/refining/improving projects (RE) |
Good local relationships | 12 | - | 12 | - | I know the people I need to work with (RG) |
Availability/ choice of RECs | 10 | 10 | - | - | Online booking systems; seeing REC meeting dates online (RE) |
Gives confidence standards met | 9 | 9 | - | - | It acts as a safeguard for vulnerable people (RE) |
Consistency | 8 | 8 | - | - | It applies a ‘yardstick’ across all studies, ensuring uniformity and consistency which is important (RE) |
Low burden on service providers | 8 | - | 8 | - | Lower administrative burden for Trusts. HRA approval letter provides clear instruction for Trust (RG) |
Sponsor support | 7 | - | 7 | - | We have a great research department who are all well versed in research - academic, healthcare, government and commercial (RG) |
Improved | 6 | 6 | - | - | Speed of panels/committees much quicker than before (RE) |
Data availability | 6 | - | - | 6 | Data coverage is continually improving (IG) |
User friendly system | 6 | - | - | 6 | Regional systems have streamlined governance and it is possible to amend applications to ask for additional years of data without going back to the start (IG) |
Simple quick process for amendments | 5 | 5 | - | - | Simple amendment system to add additional sites etc. (RE) |
Responsive | 5 | - | 5 | - | HRA are generally quick to respond and approve low risk studies (RG) |
Abbreviations: RE - Research Ethics, RG – Research Governance, IG - Information Governance.
Some respondents reported that timelines were clear and that guidance (n = 8) is available.
But even in response to this question which sought positive experiences, across the three areas of research ethics, research governance and information governance, there were many negative comments. For instance, the largest category of responses to what worked well in information governance was “nothing” or “very little” (n = 32).
Problems
This question received the most comments (n = 684 coded comments) (Table 2).
Table 2.
Theme | Total across areas n | Research ethics n | Research governance n | Information Governance n | Key quotations |
---|---|---|---|---|---|
Lack of integration of systems | 139 | 49 | 85 | 5 | Endless stream of middle managers in different organisations requiring the same information from me, not trusting information given elsewhere and not being in a position to make decisions (RG) |
Delays/ lengthy process |
141 | 49 | 66 | 26 | The lead time required to obtain data from NHSD precludes a great deal of responsive, policy-relevant research (IG) |
Bureaucratic/ repetitive/ laborious |
103 | 56 | 13 | 34 | The IRAS form is far too long and is really onerous to complete. So much of the detail requested is available in the protocol and patient information materials so it is just repetition. Why submit your protocol and repeat it all in a form? …. All of this unnecessary admin just delays submission (RE) |
Disproportionate for low risk studies/ inflexible |
95 | 71 | 18 | 6 | So many forms and boxes to complete for ethics for a simple qualitative interview study. The whole system started with RCTs and has never really moved beyond them (RE) |
Inconsistent | 35 | 23 | - | 12 | Unwarranted variance in interpretations of differing Information Governance teams (IG) |
Out of touch/ unethical/ excluding |
34 | 22 | 12 | - | Procedures often exclude vulnerable people due to definitions of capacity whereas participatory research takes consent as a process throughout the research .… there are no tiered procedures that enable applicability to the research at hand. One size doesn’t and can’t fit all. (RE) |
Lack of clarity | 42 | 21 | - | 21 | Poor understanding of the law around IG, resulting in conflicting advice and policies even within the same organisation. (IG) |
Attitudes of staff/ committees: risk averse/ defensive/ aggressive |
21 | 5 | 16 | - | The defensive attitude and slowness of many R&D departments, and their ability to make you feel like you’re a dangerous threat (RG) |
Lack of specialist understanding/expertise | 17 | 17 | - | - | Lack of knowledge from RECs about research on sensitive topics e.g. palliative care (RE) |
Data sharing agreements | 14 | - | - | 14 | IG departments can be very slow to process applications to conduct research. Data sharing across NHS Trusts can be extremely bureaucratic (IG) |
Expensive | 13 | 4 | - | 9 | Expense of accessing datasets sometimes means that research is not feasible (IG) |
Frequent changes to system | 11 | 7 | - | 4 | Every time I come to another project the process and the forms have changed yet again so you can’t even used what you learned last time to help you (RE) |
Availability of help/support | 8 | 8 | - | - | Challenges in finding the right person to speak with about queries or indeed finding anyone (RE) |
Additional delays for amendments | 7 | - | 7 | - | The fact that you have to get C&C again with every amendment is a complete nightmare. (RG) |
Student research requiring more guidance | 7 | - | 7 | - | Student research applications not meeting NHS HRA standards. Lot of resource invested in explaining the system and referring students back to their HE to refine their applications (RG) |
Not sticking to remit | 6 | 6 | - | - | Ethics committees requesting changes to format and designs, which has nothing to do with ethical considerations (RE) |
Poorly designed system/not user friendly | 6 | 6 | - | - | The IRAS forms are not easy to complete as you can only see two lines at a time! (RE) |
Different processes for research/ service evaluation/ improvement | 6 | 6 | - | - | The definition of the distinction between [service evaluation or research].does not make sense and is not consistent between University and NHS documentation, leading to the risk of game-playing (RE) |
Financial review additional burden | 6 | - | 6 | - | SoECAT not being accepted despite hours of work creating and getting approval. Pharmacy delays, additional local documents being requested, individual departments asking for funding despite SoECAT and saying that they don’t see any research funding. (RG) |
Pedantic | 5 | 5 | - | - | Minor changes being requested to documentation which are not really needed (RE) |
Abbreviations: RE - Research Ethics, RG – Research Governance, IG - Information Governance.
The most frequently reported problem was the complex (n = 139) and bureaucratic nature of the approvals processes with unnecessary duplication of information required (n = 103). Respondents noted that the system is not easy to use, clarity about permissions required is difficult to find – and sometimes seems arbitrary (n = 42). Support was not always available (n = 8), changes to processes were frequent (n = 11) and delays were reported to be extensive (n = 141). Systems and processes were described as inflexible and disjointed.
In particular, many respondents reported that processes are disproportionate to risk for many studies, particularly non-intervention studies, studies using routine data only and qualitative research. Several respondents described the poor fit between a system designed for clinical (randomised) trials and qualitative, participatory or other mixed methods studies which evolve during the conduct of the research (n = 95). The requirement for all study materials to be developed and submitted before any research can begin was reported to be detrimental to collaborative working, particularly with patients or the public, and resulted in the need for frequent amendments to be submitted and approved – a further time consuming process that could again cause delays to study timelines (n = 7).
Respondents reported inconsistent practice between ethics committees (n = 35), resulting in wasted time, frustration and the potential for selection of preferred committees. Related to this was the noted lack of understanding or expertise in clinical, population or methodological areas e.g. palliative care; people with mental health problems; vulnerable groups; observational/routine data/qualitative approaches (n = 17).
Several respondents reported that committees may be out of touch and that some areas of feedback that have become standard practice (e.g. lengthy and complex patient information sheets) exclude participants, particularly people with learning, communication and sensory disabilities as well as other ‘hard to reach’ groups (n = 34).
Respondents reported that there was a lack of clarity around definitions of research (which requires HRA approval) and service evaluation (which can be undertaken without ethical approval) and processes of ethics and governance - what is required, who provides what, where to seek help.
Data sharing agreements were described as very time consuming and challenging to negotiate. Variations in requirements or decisions between partners were reported by 12 respondents.
Several respondents referred to the behaviour of committees and other staff as unreasonable, defensive, risk averse, unfair and even aggressive – leaving researchers distressed and demoralised and impeding progress. Committees were reported to provide comments on study design and other aspects of the research that were felt to be out of their remit (n = 6). Newly introduced financial review processes (e.g. SoECAT – a newly introduced system for allocation of costs) were described as an additional burden (n = 6).
Impact on delivery
There were over 500 comments provided on impact on delivery – more than half of these comments related to delays (n = 300), sometimes for months or years (Table 3).
Table 3.
Theme | Total across areas n | Research ethics n | Research governance n | Information Governance n | Key quotations |
---|---|---|---|---|---|
Delays | 300 | 121 | 110 | 69 | There are delays to research even though there is no flexibility on funding (RE) |
Deters, restricts or changes research, innovation/ collaboration |
73 | 46 | 21 | 6 | We have avoided setting up studies, compromised on our sampling strategies and generally been discouraged. The general feeling is that HRA should be avoided if possible (RG) |
Workload/ difficulty/ waste | 75 | 26 | 34 | 15 | Major administrative burden (IG) |
Reduced quality | 30 | 18 | - | 12 | Perhaps the most pernicious impact is the fact that every time you want to change a sentence on a leaflet you have to go through an amendment, which is more paperwork and more delays. It basically means that you don’t bother changing things even if it would improve the study/recruitment/participant experience and the research is of lower quality as a result (RE) |
Research delivery/ performance | 30 | 17 | - | 13 | My funding ran out while I was waiting for the data to arrive, so now I cannot do anything with it. (IG) |
Staff stress/ morale | 34 | 15 | 14 | 5 | Massive, catastrophic: it now takes up more time than the research itself sapping the will to live let alone motivation to undertake research. (RE) |
Increased costs | 20 | 12 | - | 8 | The main impact is to raise the cost of the work, as researcher time is invested in negotiating a byzantine process of form-filling with significant invisible costs which are, inevitably, borne by the research funders (RE) |
Planning burden/uncertainty | 8 | 8 | - | - | Timelines unknown so can’t progress things and indicate to sites when amendments will be rolled out as unknown when approvals will be received (RE) |
System problems | 7 | 7 | - | - | Complications when submitting initial application and any subsequent amendments as comments from more than one committee can be baffling (RE) |
Inability to inform policy with timely evidence | 8 | - | - | 8 | Massive, massive delays …. consequently, investment decisions continue to be made, without any information about effectiveness. (IG) |
Abbreviations: RE - Research Ethics, RG – Research Governance, IG - Information Governance.
Many respondents (n=75) reported that processes for gaining approvals changed or deterred research, innovation and collaboration (n=73), inhibiting the production of research evidence to inform policy and practice (n = 30). For instance, respondents reported that they avoided carrying out studies with patient contact due to the requirement for ethical and governance approvals. Approvals processes were reported to impede or block research as deadlines were missed or researchers ran out of steam.
Many respondents (n = 26) reported high workloads related to the bureaucracy of approval processes, which for some (n = 34) became stressful and affected their morale. The challenge of gaining approvals in order to start and complete research was described in the context of external funding and short-term contracts for many researchers.
Suggestions for improvement
There were many suggestions for areas to improve, and some suggestions about how this could be achieved (Table 4).
Table 4.
Theme | Total across areas n | Research ethics n | Research governance n | Information Governance n | Key quotations | |
---|---|---|---|---|---|---|
Streamline/ simplify/ standardise | 195 | 97 | 69 | 29 | Reduce information in forms, use documents submitted and protocol for key information rather than repeating in form (RE) | |
Make proportionate /better fit for non-RCTs | 79 | 52 | 27 | - | Remove the need for so many R&D approvals for low risk studies, especially at the boundary of research and audit or research and quality improvement (RG) | |
Change of attitude/ approach | 41 | 26 | - | 15 | A change in attitude and culture that aims to be more permissive and enabling – focussing on how the use of data for public good as opposed to what you can’t do (IG) | |
Support/ guidance | 44 | 18 | 12 | 14 | More worked examples to help you complete applications (RE) | |
Faster turnaround/ time targets | 20 | 15 | 5 | - | Speedier review for urgent studies without detriment to non-urgent research (RE) | |
Clarification | 42 | 11 | 19 | 12 | Clear understandable requirements so you know if you are meeting the regulations or not (IG) | |
Learn from experience | 15 | 15 | - | - | It would be good if pragmatic approach that has been used during the pandemic is continued after things start to return to normal (RE) | |
Expertise/ representation | 12 | 6 | - | 6 | The road to greater inclusivity has many components and the ethics committees can have a more prominent role in this. It is important to take steps that ethics committees are truly representative of the community – with representatives at senior levels from a broad range of minority ethnic groups (RE) |
Abbreviations: RE - Research Ethics, RG – Research Governance, IG - Information Governance.
In line with challenges described in previous questions, most suggestions related to streamlining or simplifying HRA and other processes (n = 195), in particular for low-risk research (n = 79). Suggestions about how to do this included the elimination of duplication e.g. between documentation such as study protocol and various sections of the online form; avoidance of complex arrangements; development of triage and potentially different pathways for different types of research; and a flexible approach for study designs which evolve over the period of the research.
Some respondents made suggestions about changing attitudes or overall approach – so that committees are less confrontational, less defensive, and change some assumptions about the behaviour of researchers. Respondents suggested that committees and others involved in ethics and governance processes e.g. Research Ethics Committees (RECs), Confidential Advisory Group (CAG), NHS Digital consider the balance of risks and harms to research participants and those outside the research process who may lose the benefit of the findings, should the research not go ahead or be delayed.
Several respondents asked for more provision of support, clarifications, improvements to online systems and changes to timelines to improve speed of processes.
Respondents suggested ensuring that committee membership represented the populations served, through e.g. Equality Assessment processes. Virtual processes and meetings were appreciated by some, whilst others wanted to see a return to face to face meetings.There was general agreement that inconsistencies need to be addressed e.g. through provision of standardised templates and guidance.
Discussion
Summary of key findings
The need for high quality rapid responsive HSR has never been greater given the impact of the pandemic on the NHS. This survey demonstrates that the HSR community considers there are major problems with current ethics, governance and IG approval processes applied to HSR across the NHS, and many opportunities for the system to be more streamlined, flexible and responsive.
Aspects which were reported to work well were: centralised systems e.g. IRAS; confidence in having the approval of a rigorous and respected system; helpful staff. Workload, frustration and delays related to processes which were viewed as overly bureaucratic, unclear, repetitive, inflexible and inconsistent were reported as the main problems across research ethics, governance and information governance. A theme raised across areas was the disproportionality of processes for relatively low-risk studies such as some non-interventional, qualitative, and routine (existing) data studies. Assessment of risk needs to be undertaken regardless of methodology, but current processes seem to default to an onerous and one-sided consideration of risk even for low-risk studies. Some requirements were reported to have unintended effects on inclusion and diversity, and to be a very difficult fit with Patient and Public Involvement and engagement processes. Inflexibility, the need to have everything ready at the outset with every small change requiring a lengthy amendments process and overlong, complicated Patient Information Sheets were highlighted again and again as off-putting, particularly for participants in marginalised groups. Existing processes and requirements were reported to cause stress and demoralisation for those involved in trying to produce research, particularly as most research is contracted for fixed time periods, and many researchers are employed on fixed term contracts. Impact on research delivery was reported to be high, in terms of timescales for completing studies, deterrence of research, particularly for clinicians and students, quality of outputs and costs. Many suggestions were made for improvements in each section of the questionnaire, related to system level changes / overall approach and specific refinements to existing systems. Many suggestions were made about how to try to streamline and integrate systems in order to reduce workload and speed up processes for approvals. Key players responsible for these systems - and therefore for change - include the HRA and its component parts (RECs, local R&D Offices, regional Clinical Research Networks); CAG and NHS Digital.
Study limitations
In this online survey we used a snowball approach to try to gain views and experiences from a wide range of people working in HSR in the UK. Because of this approach we do not have any data about response rate or representativeness of respondents. We used mainly open-ended questions which resulted in a large amount of narrative data to code. We discussed and validated codes to provide a descriptive analysis to present results in a coherent manner, and we carried out one level of coding only.
This survey captured mainly the views of researchers – end-users - rather than those involved directly in the various regulatory agencies.
Implications of findings
In order to thrive in the long term, research needs to be carried out responsibly, sustainably and efficiently. Structures and processes to gain permissions to undertake research in NHS settings have been developing over the last thirty years. Despite many efforts to streamline these structures and processes, there have been concerns that the regulatory journey for HSR studies has resulted in over complex, duplicative pathways that can cause delay to initiation and completion of studies and are costly to follow [13]. We have found that despite repeated attempts to streamline and integrate permissions processes for research in the NHS in the UK, researchers report that processes and systems remain bureaucratic, with long delays and high financial and personal costs. During the COVID-19 pandemic the need for research to underpin healthcare provision was even more urgent than usual due to the unprecedented volume of demand by patients who were extremely sick and lack of previous evidence or experience of this virus – risk factors; epidemiology; effective treatments; means of prevention (vaccinations) and optimal health care organisation. Changes were made to health research permissions processes in order to expedite COVID-19 related research [14, 15], with mixed success. The NHS setting offers unrivalled opportunities for health research in the UK, but complex structures and processes threaten the ability of researchers to provide timely evidence to inform policy and practice, with systems designed for high-risk interventional research not fit for purpose for low-risk studies. Findings from this survey indicate that current processes for ethical and governance approvals are not only inefficient but have impacts on speed, inclusion and capacity which fly in the face of key policy and funder objectives. Current efforts to ‘bust bureaucracy’, [16] including the current HRA initiative “Think ethics” [17] must: include a new approach to risk assessment across the whole system; reduce complexity; and improve integration of different parts of the overall system for ethics and governance in health services research. Only then can we make strides towards timely production of evidence to inform policy and practice in the UK and internationally.
Acknowledgements
We would like to thank the Board of Trustees of HSRUK for support and advice throughout study. Thank you to all respondents to the survey for contributing their data and views. The HRA and NIHR are also warmly acknowledged for their continued support throughout the study.
Authors’ contributions
HS conceptualised and led the study, carried out analysis, drafted manuscript and agreed all revisions; AK Carried out and supported analysis; provided comments on drafts and agreed final paper. RB organised questionnaire production and distribution; contributed to data curation and undertook analysis; provided comments and agreed final paper. PB provided comments at all stages and agreed final draft. KC Provided comments at all stages and agreed final draft. JE provided comments at all stages and agreed final draft. GAF contributed to study design; provided comments at all stages and agreed final draft. LL provided comments at all stages and agreed final draft. KW contributed to study conception, development of methods, design of questionnaire, analysis; provided comments at all stages and agreed final draft.
Funding
There was no funding for the study, it was supported by HSR UK and Swansea University.
Data Availability
The datasets used and/or analysed during the current study available from the corresponding author on reasonable request.
Declarations
Ethical approval and consent to participate
We confirm that ethics approval was deemed unnecessary according to UK regulations, as reflected in University processes delineated in the subsequent text. The UoM online ethics review tool was used to review if any ethical approvals were needed for our consultation. They confirmed that institutional ethical review was not required as:
•The data is completely anonymous with no personal information being collected (apart from their name, their publicly available contact details and a record of consent);
•The data is not considered to be sensitive or confidential in nature;
•The issues being researched are not likely to upset or disturb participants;
•Vulnerable or dependant groups are not included;
•There is no risk of possible disclosures or reporting obligations.
All participants were made aware in the information provided with the questionnaire that completing the questionnaire was voluntary. That by proceeding to take part in the questionnaire, they were providing informed consent. That all information would be anonymised and no identifiable data would be reported in the paper.
Consent for publication
All participants were made aware that information denoted in subsequent research articles would be anonymised so that no identifiable information would be reported in the paper. It was made clear that by participating in the questionnaire, participants were consenting to the publication of findings. Specific consent was not applicable to this study.
Competing interests
The authors declare no competing interests.
Footnotes
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
- 1.Kristensen N, Nymann C, Konradsen H. Implementing research results in clinical practice- the experiences of healthcare professionals. BMC Health Serv Res 2016; 16–48. [DOI] [PMC free article] [PubMed]
- 2.Hanney SR, Castle-Clarke S, Grant J, Guthrie S, Henshall C, et al. How long does biomedical research take? Studying the time taken between biomedical and health research and its translation into products, policy and practice. Health Res Policy Syst. 2015;13:1–18. doi: 10.1186/1478-4505-13-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Tickel A. 2022 Independent Review of Research Bureaucracy – Interim Report (https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1046070/independent-review-of-research-bureaucracy-interim-report.pdf) accessed 27.06.2022.
- 4.National Institute for Health and Care Research. 2020 (https://www.nihr.ac.uk/news/nihr-launches-new-centre-for-engagement-and-dissemination/24576) accessed 22.09.2022.
- 5.Rand Corporation. 2022 (https://www.rand.org/randeurope/research/projects/brace-nihr-rapid-service-evaluation-centre.html) accessed 23.09.2022.
- 6.Garrido MV, Kristensen FB, Nielsen CP et al. 2008. Health Technology Assessment and Health Policy Making in Europe: Current Status, Challenges and Potential. (https://www.euro.who.int/__data/assets/pdf_file/0003/90426/E91922.pdf) accessed 24.06.2022.
- 7.Bickford JJ, Kothari AR. Research and knowledge in Ontario tobacco control networks. Can J Public Health 2008:99:297–300. [DOI] [PMC free article] [PubMed]
- 8.Taylor-Robinson DC, Milton B, Lloyd-Williams F, O’Flaherty M, et al. Ahead in public health? A qualitative study of the time horizons used in public health decision-making. BMC Public Health. 2008;8:415. doi: 10.1186/1471-2458-8-415. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Lohr KN, Steinwachs DM. Health services research: an evolving definition of the field. Health Serv Res. 2002;37:7–9. [PubMed] [Google Scholar]
- 10.McDonnell A, Wilson R, Goodacre S. Evaluating and implementing new services. BMJ 20069; Jan 14;332:109–12. [DOI] [PMC free article] [PubMed]
- 11.Kingston MR, Griffiths R, Hutchings HA, et al. Emergency admission risk stratification tools in UK primary care: a cross-sectional survey of availability and use. Br Journal Gen Practice. 2020;70:740–8. doi: 10.3399/bjgp20X712793. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.NHS England. 2022 (https://transform.england.nhs.uk/covid-19-response/data-and-covid-19/information-governance/copi-notice-frequently-asked-questions) accessed 24.06.2022.
- 13.NHS Health Research Authority. 2021(https://www.hra.nhs.uk/approvals-amendments/what-approvals-do-i-need/hra-approval/) accessed 24.06.2022.
- 14.National Institute for Health and Care Research. 2022 (https://www.nihr.ac.uk/covid-studies) accessed 24.06.2022.
- 15.Thompson AG, France EF. One stop or full stop? The continuing challenges for researchers despite the new streamlined NHS research governance process. BMC Health Serv Res 2010; 124. [DOI] [PMC free article] [PubMed]
- 16.UK Government. 2022 (https://www.gov.uk/government/publications/review-of-research-bureaucracy%20accessed%2027.06.2022) accessed 27.06.2022.
- 17.NHS Health Research Authority. 2022 (https://www.hra.nhs.uk/approvals-amendments/what-approvals-do-i-need/research-ethics-committee-review/think-ethics) accessed 8/9/22.
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
The datasets used and/or analysed during the current study available from the corresponding author on reasonable request.